NZ709318A - Antibody constructs for cdh19 and cd3 - Google Patents
Antibody constructs for cdh19 and cd3 Download PDFInfo
- Publication number
- NZ709318A NZ709318A NZ709318A NZ70931814A NZ709318A NZ 709318 A NZ709318 A NZ 709318A NZ 709318 A NZ709318 A NZ 709318A NZ 70931814 A NZ70931814 A NZ 70931814A NZ 709318 A NZ709318 A NZ 709318A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody construct
- human
- binding
- cdh19
- vector
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361756991P | 2013-01-25 | 2013-01-25 | |
| US201361785147P | 2013-03-14 | 2013-03-14 | |
| PCT/EP2014/051550 WO2014114800A1 (en) | 2013-01-25 | 2014-01-27 | Antibody constructs for cdh19 and cd3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ709318A true NZ709318A (en) | 2020-12-18 |
Family
ID=50137614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ709318A NZ709318A (en) | 2013-01-25 | 2014-01-27 | Antibody constructs for cdh19 and cd3 |
Country Status (37)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008119565A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| CA2738568C (en) * | 2008-10-01 | 2024-02-20 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
| NZ591087A (en) * | 2008-10-01 | 2012-08-31 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2948478B1 (en) | 2013-01-25 | 2019-04-03 | Amgen Inc. | Antibodies targeting cdh19 for melanoma |
| JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| AU2015295242B2 (en) * | 2014-07-31 | 2020-10-22 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
| ES2743809T3 (es) * | 2014-07-31 | 2020-02-20 | Amgen Res Munich Gmbh | Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados |
| AR101669A1 (es) * | 2014-07-31 | 2017-01-04 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| SI3227339T1 (sl) | 2014-12-05 | 2022-02-28 | Memorial Sloan-Kettering Cancer Center | Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba |
| EP3227324A4 (en) * | 2014-12-05 | 2018-08-29 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
| US10227408B2 (en) | 2015-02-19 | 2019-03-12 | Compugen Ltd. | Anti-PVRIG antibodies and methods of use |
| CA3155409A1 (en) * | 2015-05-13 | 2016-11-17 | Ablynx N.V. | T cell recruiting polypeptides based on cd3 reactivity |
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| EP3328994A4 (en) * | 2015-07-31 | 2019-04-17 | Memorial Sloan-Kettering Cancer Center | CD56-Faced Antigen-Binding Proteins and Uses Thereof |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| TWI717375B (zh) * | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| CN113817060B (zh) * | 2016-01-09 | 2024-03-08 | 嘉立医疗科技(广州)有限公司 | 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞 |
| EP3411404B1 (en) | 2016-02-03 | 2022-11-09 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging antibody constructs |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN116987189A (zh) * | 2016-05-20 | 2023-11-03 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| BR112019000220A2 (pt) * | 2016-07-06 | 2019-04-24 | National Research Council Of Canada | anticorpos humanizados que transmigram a barreira hematoencefálica e usos dos mesmos |
| CN110088132B (zh) | 2016-08-17 | 2020-10-27 | 康姆普根有限公司 | 抗tigit抗体，抗pvrig抗体及其组合 |
| EP3544629A4 (en) | 2016-11-23 | 2020-06-17 | Harpoon Therapeutics, Inc. | PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF |
| CN110198955A (zh) | 2016-11-23 | 2019-09-03 | 哈普恩治疗公司 | 前列腺特异性膜抗原结合蛋白质 |
| TN2019000225A1 (en) * | 2017-02-02 | 2021-01-07 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| HRP20241268T1 (hr) | 2017-10-13 | 2024-12-06 | Harpoon Therapeutics, Inc. | Trispecifični proteini i postupci primjene |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| MA52571A (fr) * | 2018-05-08 | 2021-03-17 | Amgen Inc | Anticorps bispécifiques ayant des étiquettes appairées à des charges c-terminales clivables |
| KR20210020903A (ko) | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| SG11202103022WA (en) | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
| US12516128B2 (en) | 2019-05-14 | 2026-01-06 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| KR20220122656A (ko) | 2019-12-06 | 2022-09-02 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법 |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| WO2021226179A2 (en) * | 2020-05-05 | 2021-11-11 | University Of Massachusetts | Anti-sars-cov-2 spike protein antibodies and methods of use |
| US20240150444A1 (en) * | 2021-02-26 | 2024-05-09 | Fred Hutchinson Cancer Center | Protective antibodies against respiratory viral infections |
| MX2024002112A (es) * | 2021-08-16 | 2024-05-03 | Janssen Biotech Inc | Anticuerpos anti-vegfr1 y sus usos. |
| CN116554340A (zh) * | 2022-01-28 | 2023-08-08 | 江苏众红生物工程创药研究院有限公司 | 新型长效化和高活性且更安全的抗体构建体 |
| WO2023235805A2 (en) * | 2022-06-01 | 2023-12-07 | The Wistar Institute Of Anatomy And Biology | Dna-encoded bispecific antibodies targeting carbonic anhydrase 9 and methods of use in cancer therapeutics |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US721367A (en) | 1902-05-26 | 1903-02-24 | Andrew J Gunter | Bellows. |
| US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| ATE108965T1 (de) | 1987-12-09 | 1994-08-15 | Omron Tateisi Electronics Co | Induktives datenübertragungssystem. |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DK0575319T3 (da) | 1991-03-11 | 2000-07-10 | Univ Georgia Res Found | Kloning og ekspression af Renilla-luciferase |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| JPH07508410A (ja) | 1992-06-18 | 1995-09-21 | ジェンファーム インターナショナル インコーポレイテッド | 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法 |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| ATE240394T1 (de) | 1992-10-23 | 2003-05-15 | Immunex Corp | Methoden zur herstellung löslicher, oligomerer proteine |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| KR960705209A (ko) | 1993-09-10 | 1996-10-09 | 잭 엠. 그랜노위츠 | 녹색 형광 단백의 용도 |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| WO1997007671A1 (en) | 1995-08-29 | 1997-03-06 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for constructing the same |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| EP1015872B1 (en) | 1996-12-12 | 2005-03-02 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
| CA2324648C (en) | 1998-03-27 | 2013-02-26 | Prolume, Ltd. | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US7435871B2 (en) | 2001-11-30 | 2008-10-14 | Amgen Fremont Inc. | Transgenic animals bearing human Igλ light chain genes |
| ES2263984T3 (es) * | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| WO2005067391A2 (en) | 2004-01-19 | 2005-07-28 | Technion Research & Development Foundation Ltd. | Diagnostic test for parkinson's disease |
| WO2006007441A1 (en) * | 2004-06-16 | 2006-01-19 | Cardo Systems Inc. | Wireless communication headset with microphone switching system |
| AU2005263555B2 (en) | 2004-07-16 | 2011-01-27 | Amgen Research (Munich) Gmbh | Expression-enhanced polypeptides |
| AU2005322410B2 (en) * | 2004-11-30 | 2011-11-10 | Amgen Fremont Inc. | Antibodies directed to GPNMB and uses thereof |
| MX2007015476A (es) | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
| KR20130108481A (ko) | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| US20070161018A1 (en) * | 2005-11-04 | 2007-07-12 | Johji Inazawa | Method for detecting cancer and a method for suppressing cancer |
| EP2032719A2 (en) | 2006-06-02 | 2009-03-11 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy |
| US8430938B1 (en) | 2006-07-13 | 2013-04-30 | The United States Of America As Represented By The Secretary Of The Navy | Control algorithm for autothermal reformer |
| WO2008119565A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| RS53008B2 (sr) * | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| US8464584B2 (en) | 2007-10-19 | 2013-06-18 | Food Equipment Technologies Company, Inc. | Beverage dispenser with level measuring apparatus and display |
| CA2740310A1 (en) | 2007-11-01 | 2009-05-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Altered cadherin processing in tumor cells |
| EP2072971A1 (en) | 2007-12-17 | 2009-06-24 | Services Pétroliers Schlumberger | Variable throat venturi flow meter |
| NZ591087A (en) * | 2008-10-01 | 2012-08-31 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| WO2010056374A2 (en) * | 2008-11-17 | 2010-05-20 | Veracyte, Inc. | Methods and compositions of molecular profiling for disease diagnostics |
| EP2658739B1 (de) | 2010-12-30 | 2017-02-22 | Johnson Controls Metals and Mechanisms GmbH & Co. KG | Längsverstellvorrichtung eines kraftfahrzeugsitzes mit zwei schienenpaaren |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| JO3519B1 (ar) * | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| EP2948478B1 (en) * | 2013-01-25 | 2019-04-03 | Amgen Inc. | Antibodies targeting cdh19 for melanoma |
| AU2014236769B2 (en) * | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
| CN106796236A (zh) * | 2013-12-30 | 2017-05-31 | 促进军事医学的亨利·M·杰克逊基金会公司 | 前列腺癌基因谱和使用所述基因谱的方法 |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| ES2743809T3 (es) | 2014-07-31 | 2020-02-20 | Amgen Res Munich Gmbh | Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados |
| AR101669A1 (es) * | 2014-07-31 | 2017-01-04 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| US10105142B2 (en) | 2014-09-18 | 2018-10-23 | Ethicon Llc | Surgical stapler with plurality of cutting elements |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究（慕尼黑）公司 | Ｃｄ７０及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| EP3411404B1 (en) | 2016-02-03 | 2022-11-09 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging antibody constructs |
| CN116063544A (zh) | 2016-02-03 | 2023-05-05 | 安进研发（慕尼黑）股份有限公司 | Bcma和cd3双特异性t细胞接合抗体构建体 |
| KR20250111232A (ko) * | 2017-12-11 | 2025-07-22 | 암젠 인크 | 이중특이적 항체 생성물의 연속 제조 공정 |
-
2014
- 2014-01-26 JO JOP/2014/0017A patent/JO3519B1/ar active
- 2014-01-27 PL PL14705293T patent/PL2948477T3/pl unknown
- 2014-01-27 US US14/165,330 patent/US20140322218A1/en not_active Abandoned
- 2014-01-27 KR KR1020217007846A patent/KR102452351B1/ko active Active
- 2014-01-27 CN CN201480017626.1A patent/CN105121468B/zh active Active
- 2014-01-27 UA UAA201508287A patent/UA118749C2/uk unknown
- 2014-01-27 TW TW107103118A patent/TWI695012B/zh active
- 2014-01-27 DK DK14705293.0T patent/DK2948477T3/da active
- 2014-01-27 MY MYPI2015702403A patent/MY175075A/en unknown
- 2014-01-27 SI SI201431390T patent/SI2948477T1/sl unknown
- 2014-01-27 BR BR112015017548-1A patent/BR112015017548B1/pt active IP Right Grant
- 2014-01-27 PT PT147052930T patent/PT2948477T/pt unknown
- 2014-01-27 EP EP14705293.0A patent/EP2948477B1/en active Active
- 2014-01-27 JP JP2015554186A patent/JP6522517B2/ja active Active
- 2014-01-27 MX MX2015009594A patent/MX369149B/es active IP Right Grant
- 2014-01-27 RS RS20191539A patent/RS59633B1/sr unknown
- 2014-01-27 EP EP19202926.2A patent/EP3699194B1/en active Active
- 2014-01-27 ES ES14705293T patent/ES2759248T3/es active Active
- 2014-01-27 WO PCT/EP2014/051550 patent/WO2014114800A1/en not_active Ceased
- 2014-01-27 SG SG10201705874QA patent/SG10201705874QA/en unknown
- 2014-01-27 HU HUE14705293A patent/HUE046412T2/hu unknown
- 2014-01-27 UY UY0001035286A patent/UY35286A/es active IP Right Grant
- 2014-01-27 SG SG11201505232WA patent/SG11201505232WA/en unknown
- 2014-01-27 PE PE2015001548A patent/PE20151613A1/es active IP Right Grant
- 2014-01-27 SM SM20190739T patent/SMT201900739T1/it unknown
- 2014-01-27 NZ NZ709318A patent/NZ709318A/en unknown
- 2014-01-27 US US14/761,839 patent/US10059766B2/en active Active
- 2014-01-27 KR KR1020157022936A patent/KR102230620B1/ko active Active
- 2014-01-27 ES ES19202926T patent/ES2929276T3/es active Active
- 2014-01-27 EA EA201591376A patent/EA036950B1/ru not_active IP Right Cessation
- 2014-01-27 LT LT14705293T patent/LT2948477T/lt unknown
- 2014-01-27 HR HRP20191983TT patent/HRP20191983T1/hr unknown
- 2014-01-27 TW TW103103045A patent/TWI660971B/zh active
- 2014-01-27 CA CA2896372A patent/CA2896372C/en active Active
- 2014-01-27 AP AP2015008608A patent/AP2015008608A0/xx unknown
- 2014-01-27 AU AU2014209877A patent/AU2014209877B2/en active Active
-
2015
- 2015-07-22 IL IL240092A patent/IL240092B/en active IP Right Grant
- 2015-07-23 TN TN2015000317A patent/TN2015000317A1/en unknown
- 2015-07-24 CL CL2015002071A patent/CL2015002071A1/es unknown
- 2015-07-24 PH PH12015501651A patent/PH12015501651B1/en unknown
- 2015-08-24 ZA ZA2015/06129A patent/ZA201506129B/en unknown
- 2015-08-25 CR CR20150437A patent/CR20150437A/es unknown
-
2018
- 2018-05-14 AU AU2018203339A patent/AU2018203339A1/en not_active Abandoned
- 2018-07-20 US US16/040,927 patent/US11498964B2/en active Active
-
2019
- 2019-04-24 JP JP2019082428A patent/JP6880100B2/ja active Active
- 2019-09-13 US US16/570,129 patent/US20200071405A1/en not_active Abandoned
- 2019-12-17 CY CY20191101322T patent/CY1123005T1/el unknown
-
2020
- 2020-06-03 IL IL275114A patent/IL275114B/en unknown
-
2022
- 2022-09-19 US US17/933,277 patent/US12441796B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ709318A (en) | Antibody constructs for cdh19 and cd3 | |
| PH12018500157A1 (en) | Antibody constructs for flt3 and cd3 | |
| PH12018500216A1 (en) | Antibody constructs for cd70 and cd3 | |
| PH12018500241A1 (en) | Antibody constructs for dll3 and cd3 | |
| MX2021008367A (es) | Constructos de anticuerpos para cdh19 y cd3. | |
| PH12018500107A1 (en) | Bispecific antibody constructs binding mesothelin and cd3 | |
| MY185953A (en) | Bispecific antibody constructs binding egfrviii and cd3 | |
| PH12015501672A1 (en) | Binding molecules for bcma and cd3 | |
| SG10201909308XA (en) | Bispecific antibody constructs for cdh3 and cd3 | |
| MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
| MY191596A (en) | Igf-1r antibody and its use for the diagnosis of cancer | |
| EA202092283A1 (ru) | Конструкции антител к cdh19 и cd3 | |
| MY195946A (en) | Antibody Constructs for DLL3 and CD3 | |
| TW202615476A (zh) | Dll3及cd3抗體構築體 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JAN 2023 BY ANAQUA SERVICES Effective date: 20211215 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JAN 2024 BY ANAQUA SERVICES Effective date: 20221220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JAN 2025 BY ANAQUA SERVICES Effective date: 20231220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JAN 2026 BY ANAQUA SERVICES Effective date: 20241219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JAN 2027 BY ANAQUA SERVICES Effective date: 20251217 |